## Effects of a nutraceutical combination containing berbey yeast rice (RYR), on lipid profile in hypercholesterolemi randomised controlled trials

ClÃnica E InvestigaciÃ<sup>3</sup>n En Arteriosclerosis 28, 178-187

DOI: 10.1016/j.arteri.2016.03.002

**Citation Report** 

#	Article	IF	CITATIONS
1	Retrospective analysis of the effects of a highly standardized mixture of <em>Berberis aristata</em> , <em>Silybum marianum</em> , and monacolins K and KA in patients with dyslipidemia. Clinical Pharmacology: Advances and Applications, 2017, Volume 9, 1-7.	0.8	6
2	Single blind, multicentre, randomized, controlled trial testing the effects of a novel nutraceutical compound on plasma lipid and cardiovascular risk factors: Results of the interim analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 850-857.	1.1	12
3	Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents. Current Opinion in Lipidology, 2017, 28, 495-501.	1.2	31
4	Nutraceuticals in the management of patients with statinâ€associated muscle symptoms, with a note on realâ€world experience. Clinical Cardiology, 2018, 41, 159-165.	0.7	24
5	Different age-independent effects of nutraceutical combinations on endothelium-mediated coronary flow reserve. Immunity and Ageing, 2018, 15, 30.	1.8	5
6	Usefulness of compounds with monacolin K in a case of statins intolerance. ClÃnica E Investigación En Arteriosclerosis, 2018, 30, 268-270.	0.4	2
7	A single blind, multicenter, randomized controlled trial to evaluate the effectiveness and cost of a novel nutraceutical (LopiGLIK <sup>®</sup> ) lowering cardiovascular disease risk. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 601-609.	0.7	3
8	Update on the Benefits and Mechanisms of Action of the Bioactive Vegetal Alkaloid Berberine on Lipid Metabolism and Homeostasis. Cholesterol, 2018, 2018, 1-17.	1.6	35
9	Policosanol composition, antioxidant and anti-arthritic activities of milk thistle (Silybium marianum) Tj ETQq0 0 0	rgBT /Ove	erlgçk 10 Tf 5
10	Berberine Modulates LPA Function to Inhibit the Proliferation and Inflammation of FLS-RA via p38/ERK MAPK Pathway Mediated by LPA <sub>1</sub> . Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-12.	0.5	19

11	Effects of a Novel Nutraceutical Combination (Aquilea Colesterol®) on the Lipid Profile and Inflammatory Biomarkers: A Randomized Control Trial. Nutrients, 2019, 11, 949.	1.7	8
12	Effects of berberine on glucose-lipid metabolism, inflammatory factors and insulin resistance in patients with metabolic syndrome. Experimental and Therapeutic Medicine, 2019, 17, 3009-3014.	0.8	18
13	Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine. Frontiers in Pharmacology, 2019, 10, 1449.	1.6	59
14	NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. Atherosclerosis, 2019, 280, 51-57.	0.4	20
15	Potential cytotoxic and anti-metastatic effects of berberine on gynaecological cancers with drug-associated resistance. European Journal of Medicinal Chemistry, 2020, 187, 111951.	2.6	33
16	Exposure to the natural alkaloid Berberine affects cardiovascular system morphogenesis and functionality during zebrafish development. Scientific Reports, 2020, 10, 17358.	1.6	10
17	Comparative effect of nutraceuticals on lipid profile: a protocol for systematic review and network meta-analysis. BMJ Open, 2020, 10, e032755.	0.8	5
18	Optimized microwave assisted extraction (MAE) of alkaloids and polyphenols from Berberis roots using multiple-component analysis. Scientific Reports, 2020, 10, 917.	1.6	46

#	Article	IF	CITATIONS
19	Efficacy and Safety of Armolipid Plus®: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Nutrients, 2021, 13, 638.	1.7	15
20	Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovascular Therapeutics, 2021, 2021, 1-8.	1.1	2
21	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Current Pharmaceutical Design, 2019, 25, 85-95.	0.9	11
22	Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis. Contemporary Cardiology, 2021, , 615-636.	0.0	0
26	Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review. Molecular Biology Reports, 2022, 49, 10885-10893.	1.0	3
27	Low-density lipoprotein-cholesterol lowering effect of a nutraceutical regimen with or without ezetimibe in hypercholesterolaemic patients with statin intolerance. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
28	Berberine Reverses the Tumorigenic Function of Colon Cancer Cell-Derived Exosomes. Tohoku Journal of Experimental Medicine, 2023, 260, 75-85.	0.5	2